Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI
Oncotelic Therapeutics (OTCQB:OTLC) has published groundbreaking research on glioblastoma (GBM) treatment, revealing that high TGFB2 gene methylation correlates with improved overall survival in patients, surpassing the predictive value of MGMT and TGFB1 methylation.
The study identified several genes and pathways linked to TGFB2 methylation that improve survival outcomes, including T-cell activation, antigen processing, and Toll-like receptor pathways. The research also found that MALT1 mRNA negatively impacted survival rates, suggesting a potential target for therapy.
To facilitate research collaboration, Oncotelic has launched its proprietary PDAOAI communication platform, allowing researchers to interact with the paper and referenced articles through a single interface. This marks the company's first publication utilizing their proprietary AI technology.
Oncotelic Therapeutics (OTCQB:OTLC) ha pubblicato una ricerca innovativa sul trattamento del glioblastoma (GBM), rivelando che un'elevata metilazione del gene TGFB2 è correlata a una maggiore sopravvivenza globale nei pazienti, superando il valore predittivo della metilazione di MGMT e TGFB1.
Lo studio ha identificato diversi geni e percorsi legati alla metilazione di TGFB2 che migliorano gli esiti di sopravvivenza, inclusi l'attivazione delle cellule T, l'elaborazione degli antigeni e i percorsi dei recettori tipo Toll. La ricerca ha anche scoperto che l'mRNA di MALT1 influenzava negativamente i tassi di sopravvivenza, suggerendo un potenziale bersaglio terapeutico.
Per facilitare la collaborazione nella ricerca, Oncotelic ha lanciato la sua piattaforma di comunicazione proprietaria PDAOAI, che consente ai ricercatori di interagire con l'articolo e gli articoli di riferimento attraverso un'unica interfaccia. Questo segna la prima pubblicazione dell'azienda che utilizza la propria tecnologia AI proprietaria.
Oncotelic Therapeutics (OTCQB:OTLC) ha publicado una investigación innovadora sobre el tratamiento del glioblastoma (GBM), revelando que una alta metilación del gen TGFB2 se correlaciona con una mejor supervivencia global en los pacientes, superando el valor predictivo de la metilación de MGMT y TGFB1.
El estudio identificó varios genes y vías relacionadas con la metilación de TGFB2 que mejoran los resultados de supervivencia, incluyendo la activación de células T, el procesamiento de antígenos y las vías de los receptores tipo Toll. La investigación también encontró que el ARNm de MALT1 impactó negativamente las tasas de supervivencia, sugiriendo un posible objetivo para la terapia.
Para facilitar la colaboración en la investigación, Oncotelic ha lanzado su plataforma de comunicación propietaria PDAOAI, que permite a los investigadores interactuar con el documento y los artículos de referencia a través de una única interfaz. Esta es la primera publicación de la empresa que utiliza su tecnología de IA propietaria.
온코텔릭 테라퓨틱스 (OTCQB:OTLC)는 교모세포종 (GBM) 치료에 대한 획기적인 연구를 발표하며, 높은 TGFB2 유전자 메틸화가 환자의 전반적인 생존율 향상과 관련이 있음을 밝혔습니다. 이는 MGMT 및 TGFB1 메틸화의 예측 가치를 초월합니다.
이 연구는 TGFB2 메틸화와 관련된 여러 유전자 및 경로를 확인하여 생존 결과를 개선하는데 기여하는데, 여기에는 T 세포 활성화, 항원 처리 및 톨 유사 수용체 경로가 포함됩니다. 연구는 또한 MALT1 mRNA가 생존율에 부정적인 영향을 미친다는 것을 발견하여, 치료의 잠재적 표적이 될 수 있음을 시사합니다.
연구 협업을 촉진하기 위해, 온코텔릭은 연구자들이 단일 인터페이스를 통해 논문 및 참조 기사와 상호작용할 수 있도록 하는 독점 PDAOAI 통신 플랫폼을 출시했습니다. 이는 회사의 독점 AI 기술을 활용한 첫 번째 출판물입니다.
Oncotelic Therapeutics (OTCQB:OTLC) a publié des recherches révolutionnaires sur le traitement du glioblastome (GBM), révélant qu'une forte méthylation du gène TGFB2 est corrélée à une amélioration de la survie globale des patients, surpassant la valeur prédictive de la méthylation de MGMT et TGFB1.
Cette étude a identifié plusieurs gènes et voies liés à la méthylation de TGFB2 qui améliorent les résultats de survie, y compris l'activation des cellules T, le traitement des antigènes et les voies des récepteurs de type Toll. La recherche a également révélé que l'ARNm de MALT1 avait un impact négatif sur les taux de survie, suggérant un potentiel cible pour la thérapie.
Pour faciliter la collaboration en recherche, Oncotelic a lancé sa plateforme de communication propriétaire PDAOAI, permettant aux chercheurs d'interagir avec l'article et les articles référencés à travers une seule interface. Cela marque la première publication de l'entreprise utilisant sa technologie d'IA propriétaire.
Oncotelic Therapeutics (OTCQB:OTLC) hat bahnbrechende Forschung zur Behandlung von Glioblastomen (GBM) veröffentlicht, die zeigt, dass eine hohe TGFB2-Genmetylierung mit einer verbesserten Gesamtüberlebensrate bei Patienten korreliert, was den prädiktiven Wert der MGMT- und TGFB1-Metylierung übertrifft.
Die Studie identifizierte mehrere Gene und Wege, die mit der TGFB2-Metylierung verbunden sind und die Überlebensraten verbessern, einschließlich der Aktivierung von T-Zellen, der Antigenverarbeitung und der Toll-like-Rezeptor-Wege. Die Forschung ergab auch, dass die MALT1-mRNA die Überlebensraten negativ beeinflusste, was auf ein potenzielles Ziel für die Therapie hinweist.
Um die Forschungskollaboration zu erleichtern, hat Oncotelic seine proprietäre PDAOAI-Kommunikationsplattform gestartet, die es Forschern ermöglicht, über eine einzige Schnittstelle mit dem Papier und den referenzierten Artikeln zu interagieren. Dies ist die erste Veröffentlichung des Unternehmens, die ihre proprietäre KI-Technologie nutzt.
- First successful implementation of proprietary AI technology in published research
- Discovery of TGFB2 methylation as a superior prognostic marker for GBM treatment
- Identification of new potential therapeutic target (MALT1) for drug development
- None.
AGOURA HILLS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic,” the “Company,” or “We”), a leader in RNA-based therapeutics, today announced the publication of its latest research paper, titled, “Positive Prognostic Overall Survival Impacts of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients.” The paper, authored by Sanjive Qazi, Michael Potts, Scott Myers, Stephen Richardson, and Vuong Trieu, is available online at: https://www.mdpi.com/2072-6694/17/7/1122
To facilitate deeper exploration and discussion of this research by the research community, Oncotelic is introducing its proprietary communication platform powered by PDAOAI. PDAOAI enables users to query this paper and dozens of referenced articles through a single interactive interface. Scientists and clinicians are invited to engage at: https://discord.gg/jz6Q7G2SBQ
A Simple Summary
Glioblastoma (GBM) is one of the most aggressive brain tumors in adults. It is well established that methylation of the O-6-methylguanine-DNA methyltransferase (MGMT) gene is predictive of overall survival (OS) benefits in patients receiving standard temozolomide and radiotherapy. Transforming growth factor beta (TGFB) is a family of cytokines involved in vital cellular processes and the regulation of growth factors.
The study’s novel discovery demonstrates that high TGFB2 gene methylation correlates with an improved OS risk, surpassing the predictive value of MGMT and TGFB1 methylation when controlling for age and sex. Several genes and pathways linked to TGFB2 methylation, including immune mechanisms such as T-cell activation, antigen processing, and Toll-like receptor pathways, were identified as improving survival outcomes in GBM patients. Of note, mucosa-associated lymphoid tissue lymphoma translocation protein, also referred to as MALT1, mRNA negatively impacted survival rates, suggesting a potential avenue for targeted therapies.
“The complexity of the publication was simplified into a concise statement by our PDAOAI platform, demonstrating the power of this platform for scientific communication: The findings underscore the importance of TGFB2 methylation as a prognostic marker in GBM treatment. High levels of TGFB2 methylation are associated with improved overall survival, particularly in young adult males. This suggests that TGFB2 methylation could be a valuable biomarker for risk stratification and therapeutic targeting in GBM, potentially guiding treatment decisions and improving patient outcomes.” – Dr. Vuong Trieu, CEO of Oncotelic and co-author of the study.
“Our findings present an actionable opportunity to improve GBM patient outcomes by integrating sophisticated predictive analytical platforms and tools with clinical data. By uncovering insightful methylation patterns and elucidating gene-expression profiles at the biochemical pathway level, we expand our capacity to identify potential therapeutic targets. This approach supports the development of tailored treatment strategies through our nano-technology drug delivery platform. Ultimately, these insights enhance innovation in targeted therapies, driving improved clinical efficacy and patient survival rates in this devastating disease.” – Dr. Sanjive Qazi, lead researcher
“This is the first paper we have published that utilized our proprietary AI technology. We are excited to see our technology being applied in real-world scenarios, and we look forward to the advancements it can potentially bring in the future.” – Scott Myers, Product Manager
About Oncotelic
Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2DAO, the actual filing of a registration statement and approval of the PDAO, or any other tokens that we may launch, as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable, the success of PDAOAI platform in being used extensively by anyone outside of the Company. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the Company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K, filed with the SEC on April 12, 2024 and in the Company's other periodic and current filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the Company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.
Contact Information:
Investor Relations
ir@oncotelic.com
FAQ
What is the significance of TGFB2 methylation in GBM treatment according to OTLC's research?
How does OTLC's new PDAOAI platform enhance research collaboration?
What key pathways did OTLC's research identify for improving GBM survival outcomes?
What potential therapeutic target did OTLC's research identify in GBM treatment?
